Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-10
2005-05-10
Nguyen, Dave T. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S450000, C424S001210
Reexamination Certificate
active
06890901
ABSTRACT:
Pharmaceutical compositions comprising a mixture of hyaluronic acid and liposomes. Preferably, the pharmaceutical compositions further include a pharmaceutically active substance such as cyclosporin A encapsulated in the liposomes. A method for preparing a pharmaceutical composition includes producing liposomes from phospholipids, preferably in the presence of a pharmaceutically active substance (most preferably cyclosporin A) to be encapsulated within the liposomes, and mixing the liposomes with hyaluronic acid. Pharmaceutical compositions of this invention are used, for example, to topically administer pharmaceutical agents effective to treat skin disorders by deposition of that agent in the dermis or sub-dermis while minimizing systemic circulation thereof. These compositions are also administered orally, parenterally and intrarectally.
REFERENCES:
patent: 4517295 (1985-05-01), Bracke et al.
patent: 4708861 (1987-11-01), Popescu et al.
patent: 4861580 (1989-08-01), Janoff
patent: 5244672 (1993-09-01), Huc et al.
patent: 5344644 (1994-09-01), Igari et al.
patent: 5401511 (1995-03-01), Margalit
patent: 5437867 (1995-08-01), Vichroski et al.
patent: 5469854 (1995-11-01), Unger
patent: 5542935 (1996-08-01), Unger et al.
patent: 5585109 (1996-12-01), Hayward et al.
patent: 5585112 (1996-12-01), Unger et al.
patent: 5632995 (1997-05-01), Wade
patent: 5654000 (1997-08-01), Poli et al.
patent: 5760023 (1998-06-01), Farrar et al.
patent: 6043237 (2000-03-01), Meadows et al.
patent: 446931 (1991-09-01), None
patent: 0 446 931 (1991-09-01), None
patent: 656213 (1995-06-01), None
patent: 697214 (1996-02-01), None
patent: 2 614 787 (1988-11-01), None
patent: 2614787 (1988-11-01), None
patent: 2622104 (1989-04-01), None
patent: 2226002 (1990-06-01), None
patent: 2 226 002 (1990-06-01), None
patent: 3-143540 (1991-06-01), None
patent: WO 9009778 (1990-09-01), None
patent: WO 9214445 (1992-09-01), None
patent: WO 9214446 (1992-09-01), None
patent: WO 9214448 (1992-09-01), None
patent: WO 9316732 (1993-09-01), None
patent: WO 9614083 (1996-05-01), None
patent: WO 9715330 (1997-05-01), None
Waldrep et. al.; Cyclosporin A liposome aerosol,(1993) Internat. J. Pharm 97(1-3):205-212, abstract only.*
Yonemitsu et. al.; HVJ -catatonic liposomes: a novel and potentially effective . . . gene transfer to the airway epithelium,(1997) Gene Therapy 4(7):631-638, abstract only.*
Keenan et al (Transplantation 53(1): 20-25, 1992).*
Gilbert et al (Transplantation 56(4): 974-977, 1993).*
Tristani-Firouzi et al (Cutis 61(2 Suppl), 1998).*
Geilen et al (Clin. Exp. Rheumatol. 20(6 Suppl): S871-87, 2002).*
Opthalmed Products, viscoelastic solutions, retrieved from http//www.opthalmed.com/products/page2 on Jan. 15, 2002. See p. 2 of attached print out.*
rxhope.com, record 2246, s0dium hyaluronate, retrieved on Feb. 9, 2001.*
Verma et al. Nature 389: 239-242, especially p. 239, Sep. 1997.*
Anderson et al. Nature 392: 25-30, especially pp. 25 and 30, Apr. 1997.*
N. Weiner et al. “Topical Delivery of Liposomally Encapsulated Interferon Evaluated in a Cutaneous Herpes Guinea Pig Model” (Antimicrob. Agents Chemother., vol. 33, No. 8, pp. 1217-1221 (1989)).
K. Egbaria et al., “Liposomes as a Topical Drug Delivery System” (Advanced Drug Delivery Reviews, 5 (1990) pp. 287-300).
K. Egbaria et al. “Topical Application of Liposomally Entrapped Ciclosporin Evaluated by in vitro Diffusion Studies w/Human Skin1” (Skin Pharmacol 1991; 4:21-28).
S. M. Niemiec et al. “The effect of dosing volume on the disposition of cyclosporin A in hairless mouse skin after topical appl of a non-ionic liposomal formulation” (S.T.P. Pharma Sciences 4 (2) 145-149 (1994)).
K. Egbaria et al. “Topical Delivery of Ciclosporin: Evaluation of Various Formulations Using in vitro Diffusion Studies in Hairless Mouse Skin1” (Skin Pharmacol 1990; 3:21-28).
L.D. Mayer et al. “Solute Distributions and Trapping Efficiencies Observed in Freeze-Thawed Multilamellar Vesicles” (Biochimica et Biophysica Acta 817, pp. 193-196 (1985)).
J. du Plessis et al. “Topical Delivery of Liposomally Encapsulated Gamma-Interferon” (Antiviral Research 18, pp. 259-265 (1992)).
Ho et al. “Mechanisms of Topical Delivery of Liposomally Entrapped Drugs” Second Int'l Symposium on Recent Advances in Drug Delivery Systems, Feb. 27-28 & Mar. 1, 1985 Salt Lake City, UT USA 61-65 (1985)).
Mezei et al. “Liposomes—A Selective Drug Delivery System for the Topical Route of Administration” (Life Sciences, vol. 26, pp. 1473-1477 (1980)).
Ganesan et al. “Influence of Liposomal Drug Entrapment on Percutaneous Absorption” (International Journal of Pharmaceutics, 20: 139-154 (1984)).
J. du Plessis et al. “The Influence of Particle Size of Liposomes on the Deposition of Drug into Skin” (International Journal of Pharmaceutics, 103: 277-282 (1994)).
Gilhar et al. “Topical Cyclosporine in Psoriasis,” American Journal of Dermatology, Correspondence—Letter to the Editor, vol. 18, No. 2, Part 1, pp. 378-379 (1988).
Hermann et al. “Topical Ciclosporin for Psoriasis: In vitro Skin Penetration and Clinical Study” (Skin Pharmacol 1988; 1:246-249).
Rosier et al. “A Rapid Method for Separating Small Vesicles from Suspension” (Analytical Biochemistry 96: 384-390 (1979)).
Laurent et al. “Functions of Hyaluronan” (Journals of the Rheumatic Diseases 1995; 54: 429-432).
Suzuki et al. “The Application of Liposomes to Cosmetics” (Cosmetics & Toiletries, vol. 105 (1990) pp. 65-78).
Mezei “Liposomes as a Skin Drug Delivery System” (Elsevier Science Publishers B.V. (Biomedical Division), pp. 345-358 (1985)).
Syennikova et al. “Farmatsevtychnyi Zhurnal (Kiev)” (Khark Enterp. Prod. Immunobiol. Med. Prep. “BIOLEK”, Kharkov, UKR Farmatsevtychnyi Zhurnal (Kiev) pp. 37-40 (1993)) Ukrainian (English Abstract Attached).
Kawaguchi et al. “The Effects of Polysaccharide Chain-Length in Coating Liposomes with Partial Palmitoyl Hyaluronates” (Carbohydrate Polymers 18 (1992) pp. 139-142).
Margalit “Liposome-Mediated Drug Targeting in Topical and Regional Therapies” (Critical Reviews in Therapeutic Drug Carrier Systems, 12(2&3): pp. 233-261 (1995)).
Haynes et al. “Measurement of an Adhesion Molecule as an Indicator of Inflammatory Disease Activity” (Arthritis and Rheumatism, vol. 34, No. 11 (1991) pp. 1434-1443).
Greaves et al. “Treatment of Diseases of the Eye with Mucoadhesive Delivery Systems” (Advanced Drug Delivery Reviews, 11 (1993) pp. 349-383).
Zignani et al. “Topical Semi-Solid Drug Delivery: Kinetics and Tolerance of Ophthalmic Hydrogels” (Advanced Drug Delivery Reviews 16 (1995) pp. 51-60).
Bourlais et al. “New Ophthalmic Drug Delivery Systems” (Drug Development and Industrial Pharmacy, 21(1), pp. 19-59 (1995)).
Fillit et al. “Immunogenicity of Liposome-Bound Hyaluronate in Mice” (J. Exp. Med. © The Rockefeller University Press, vol. 168 (1988) pp. 971-982).
Thomson, “Immunology of Cyclosporin A—A Review,” Aust. J. Exp. Biol. Med. Sci., 61 (Pt. 2) pp. 147-172 (1983).
Williams et al., “Intravenous Cyclosporine and Kidney Function: The Johns Hopkins Experience,” Transplantation Proceedings, vol. XVIII, No. 2, Suppl 1), pp. 66-68 (Apr. 1985).
Ellis et al., “Cyclosporine Improves Psoriasis in a Double-blind Study,” JAMA, vol. 256, No. 22, pp. 3110-3116 (Dec. 12, 1986).
Griffiths et al., “Total Cyclosporin and Psoriasis,” The Lancet, p. 806 (Apr. 4, 1987).
Luke et al., Effects of Cyclosporine on the Isolated Perfused Rat Kidney, Transplantation, vol. 43, No. 6, p. 795 (© 1987).
Mahato et al. “Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives”, Pharmaceutical Research, vol. 14, No. 7, (1997).
PCT International Search Report (PCT/GB97/02665
Brown Marc Barry
Marriott Christopher
Martin Gary Peter
Jagotec AG
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Nguyen Dave T.
Schnizer Richard
LandOfFree
Hyaluronic drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hyaluronic drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hyaluronic drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3367950